Last reviewed · How we verify
NCT00963755
Impact of F-18-Fluorocholine PET/CT and MR Imaging/ Spectroscopy in the Management of Primary and Recurrent Prostate Cancer
trial in Prostate Cancer in 60 participants. Completed in 1 January 2018.
1 December 2017
Quick facts
| Lead sponsor | University of Lausanne Hospitals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 August 2009 |
| Primary completion | 1 December 2017 |
| Estimated completion | 1 January 2018 |
| Sites | 1 location across Switzerland |
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
University of Lausanne Hospitals
Who can join
Under 80, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Sensitivity and specificity of FCH PET/CT, MR imaging, 3-D MR spectroscopy, and fusion PET/MR imaging for the intraprostatic localization of cancer in patients with radical prostatectomy as compared to histology as the gold standard
Time frame: After prostatectomy (week 7-9 if Gleason score ≥ 8, week 7-15 if Gleason <8) -
For prostate cancer patients with relapse: To determine the impact of FCH-PET imaging for localizing relapse patients in patients with biochemical failure as compared to the standard clinical workup
Time frame: After PET/CT, week 1-2
Sponsor's own description
The purpose of this study is to demonstrate that realization of guided biopsies by multimodal imaging with 18F-fluorocholine PET / CT and MR Imaging/spectroscopy would allow to increase the rate of detection prostate cancer compared with the current approach and give an information about location and tumoral volume before surgery.:
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.
Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, et al · · 2014 · cited 10× · PMID 24559451 · DOI 10.2217/fon.13.196
Verify or expand the search:
- PubMed search for NCT00963755
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Other University of Lausanne Hospitals trials
Trials by the same sponsor.
- NCT06912906 — Feasibility Study to Compare Two Ventilatory Modes for Mechanical Ventilation Weaning · NA · not yet recruiting
- NCT06482489 — Accurate Prostate Cancer Following Using Low-Field MRI (Low-PRISM) · recruiting
- NCT06552832 — CAVEAT: An Open-Trial Feasibility Study · NA · recruiting
- NCT05927324 — Clinician-Assisted Videofeedback Exposure-Approach Therapy (CAVEAT) Trial · NA · recruiting
- NCT06320457 — A Brief Case Management Intervention for People Involuntarily Admitted to a Psychiatric Hospital · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00963755 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Lausanne Hospitals
- Last refreshed: 22 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00963755.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing